Atriva Therapeutics GmbH
๐ฉ๐ชGermany
- Country
- ๐ฉ๐ชGermany
- Ownership
- Holding
- Established
- 2015-01-01
- Employees
- 11
- Market Cap
- -
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Food Effect and DDI of Ascending Doses of the MEK Inhibitor Zapnometinib
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Atriva Therapeutics GmbH
- Target Recruit Count
- 96
- Registration Number
- NCT05555823
- Locations
- ๐ฉ๐ช
Atriva study site, Neu-Ulm, Germany
Clinical Trial to Evaluate the Safety and Efficacy of ATR-002 in Adult Hospitalized Patients With COVID-19
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2022-09-22
- Lead Sponsor
- Atriva Therapeutics GmbH
- Target Recruit Count
- 133
- Registration Number
- NCT04776044
- Locations
- ๐ฎ๐ณ
Atriva study site 91004, Raipur, India
๐ฉ๐ชAtriva study site 49012, Rostock, Germany
๐ฉ๐ชAtriva study site 49013, Berlin, Germany
Phase 1 Study of ATR-002
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2020-05-13
- Lead Sponsor
- Atriva Therapeutics GmbH
- Target Recruit Count
- 70
- Registration Number
- NCT04385420
- Locations
- ๐ง๐ช
SGS Life Sciences, Clinical Pharmacology Unit Antwerpen, Antwerp, Belgium
ยฉ Copyright 2024. All Rights Reserved by MedPath